Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 12/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.66 |
| ▸ | AHCYL1 | O43865 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neoplanocin A SCHEMBL30001474 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL12174034 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL30543748 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL29708080 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL17117192 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL12157269 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL10469277 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| Neoplanocin A SCHEMBL10576831 | 1.00 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| SCHEMBL15396253 | 0.90 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 | |
| SCHEMBL29711226 | 0.90 | AHCY (1.00) | AHCYEZH2AHCYL1ADORA3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023159062-A2 | ANABOLIC DRUGS STIMULATING TYPE II COLLAGEN PRODUCTION FROM CHONDROCYTES OR THEIR PROGENITORS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023159062-A2 | ANABOLIC DRUGS STIMULATING TYPE II COLLAGEN PRODUCTION FROM CHONDROCYTES OR THEIR PROGENITORS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY SCIENCE TECH & RES (SG) | 2016-01-21 | — | — | US | disclosed |
| US-8969313-B2 | Methods and compounds for preventing and treating a tumour | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-03 | — | — | US | disclosed |
| US-8642602-B2 | Method of inhibiting fibrogenesis and treating fibrotic disease | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642602-B2 | Method of inhibiting fibrogenesis and treating fibrotic disease | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| WO-2009058102-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-05-07 | — | — | WO | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
| US-4859677-A | Nucleoside analogues having antiviral activity | UNIVERSITY OF KANSAS (US) | 1989-08-22 | — | — | US | disclosed |
| US-4797479-A | ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | AHCY 2998/4885EZH2 1656/4885AHCYL1 1805/4885 |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | HDAC1, HDAC11, CCAR2 | AHCY 329/4885EZH2 1088/4885AHCYL1 464/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | AHCY 217/4885EZH2 1731/4885AHCYL1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.